Literature DB >> 17592352

Dexmedetomidine does not reduce epileptiform discharges in adults with epilepsy.

Pekka Talke1, Claudia Stapelfeldt, Paul Garcia.   

Abstract

There are limited data on the effect of dexmedetomidine on epileptiform electroencephalogram (EEG). The aim of this study was to investigate if dexmedetomidine will abolish epileptiform discharges in patients with medically refractory seizure disorders who were candidates for surgery to resect foci of epileptic activity. With approval from the Institutional Review Board and written informed consent, we enrolled 5 patients with medically intractable seizures who were undergoing continuous video/EEG monitoring. EEG and hemodynamic values were recorded from 15 minutes before, during, and for 60 minutes after a 60-minute dexmedetomidine infusion. Epileptiform discharges were counted for each 15-minute epoch during the study. Two of the 5 patients had a discrete spike focus in each hemisphere. Thus, we analyzed the activity of 7 distinct foci. Epileptiform activity did not decrease in any individual focus during dexmedetomidine infusion. Although dexmedetomidine did not have a statistically significant effect on interictal epileptiform activity for the group as a whole, the activity of 4 foci increased during dexmedetomidine infusion. Dexmedetomidine did not reduce seizure focus activity and thus may be a suitable anesthetic adjunct during seizure surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592352     DOI: 10.1097/ANA.0b013e318060d281

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  5 in total

1.  Retrospective Review of Critically Ill Patients Experiencing Alcohol Withdrawal: Dexmedetomidine Versus Propofol and/or Lorazepam Continuous Infusions.

Authors:  Kimberly A Ludtke; Kevin S Stanley; Natalie L Yount; Richard D Gerkin
Journal:  Hosp Pharm       Date:  2015-03

Review 2.  Alcohol Withdrawal Syndrome in Neurocritical Care Unit: Assessment and Treatment Challenges.

Authors:  Salia Farrokh; Christina Roels; Kent A Owusu; Sarah E Nelson; Aaron M Cook
Journal:  Neurocrit Care       Date:  2020-08-13       Impact factor: 3.210

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine.

Authors:  Maud A S Weerink; Michel M R F Struys; Laura N Hannivoort; Clemens R M Barends; Anthony R Absalom; Pieter Colin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Development of wirelessly-powered, extracranial brain activator (ECBA) in a large animal model for the future non-invasive human neuromodulation.

Authors:  Hyungwoo Lee; Jin San Lee; Yeongu Chung; Woo Ram Chung; Sang Joon Kim; Joon Seong Kang; Sung Min Park; Wonok Kang; Dae Won Seo; Duk L Na; Young-Min Shon
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

5.  Dexmedetomidine administration in a patient with status epilepticus under color density spectral array monitoring.

Authors:  Shinju Obara; Koh Kakinouchi; Jun Honda; Yoshie Noji; Chie Hanayama; Masahiro Murakawa
Journal:  JA Clin Rep       Date:  2019-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.